期刊文献+

膜联蛋白A2特异性siRNA的设计合成及干扰效率分析 被引量:2

Analysis on design synthesis and interferential efficiency of specific siRNA of ANXA2
下载PDF
导出
摘要 目的设计合成并筛选出高效的膜联蛋白A2(ANXA2)特异性小干扰RNA(siRNA)干扰片段,以进行后续试验。方法根据ANXA2 mRNA序列,设计编码siRNA的DNA序列,克隆入表达载体(ANXA2-siRNA1-3),与过表达载体共转染293T细胞,筛选有效干扰片段。结果 ANXA2-siRNA3可高效干扰外源性ANXA2的表达,具有较高的干扰效率。结论成功筛选出ANXA2的高效干扰片段,为下一步研究打下基础。 Objective To design,synthesize and screen the highly efficient and specific siRNA interference fragment of annexin A2(ANXA2)for conducting the follow-up experiment.Methods The DNA sequence of siRNA was designed and encoded according to ANXA2 mRNA sequence,then cloned into the expression vector(ANXA2-siRNA1-3),which and the over-expression vector were co-transfected to the 293 T cells for screening the effectively interferential fragment.Results ANXA2-siRNA3 could efficiently interfere in the expression of exogenous ANXA2 with higher interferential efficiency.Conclusion The highly efficient interferential fragment of ANXA2 is successfully screened out,which lays the foundation for the further research.
作者 许耀辉 李娜
出处 《检验医学与临床》 CAS 2016年第2期186-188,共3页 Laboratory Medicine and Clinic
基金 2014年江苏省无锡市科技局指导项目
关键词 RNA干扰 膜联蛋白A2 抗磷脂综合征 RNA interference annexin A2 antiphospholipid syndrome
  • 相关文献

参考文献10

  • 1Fabrizio M, Francesca RS, Cristiano A, et al. Subclinical atheroselerosis in systemic lupus erythematosus and an- tiphospholipid syndrome: focus on t32GPI-specific T cell response[J]. Arterioscler Thromb Vase Biol, 2014, 34 (3) :661-668.
  • 2Kwon M,Yoon CS,Jeong W,et al. ANXA2-S100A10 het- erotetramer,a novel suhstrate o{ thioredoxin[J]. J Biol Chem, 2005,280 (25) : 23584-23592.
  • 3Zhang JL, McCrae KR. Annexin A2 mediates endothdial cell activation by antiphospholipid/anti beta2-glycoprotein I antibodies[J]. Blood, 2005,105 (5) : 1964-1969.
  • 4Anna B, Jonathan NT, Chaim P. High antiphospholipid antibody levels are associated with statin use and may re- {lect chronic endothelial damage in non-autoimmune thrombosis : cross-sectional study[J]. J Clin Pathol, 2012, 65(6) :551-556.
  • 5Tong M, Viall CA, Chamley LW. Antiphospholipid anti- bodies and the placenta= a systematic review of their in vitro effects and modulation by treatment[J]. Hum Re- prod Update,2015,21(1) :97-118.
  • 6Siqing S, Yong L,Peilin H, et al. Inhibition of BT-H4 gene expression by RNA interference (RNAi) in lung cancer A549 cell iine[J]. Eur Respir J,2011,38(55) :1489.
  • 7Johanson TM, Lew AM, Chong MM. MieroRNA inde- pendent roles of the RNase III enzymes Drosha and Dicer [J] Open Biol,2013,3(10) :130-144.
  • 8Scherer L,Rossi JJ. Recent applications of RNAi in mam- malian systems [J]. Curr Pharm Biotechnol, 2004,5 (3):355-360.
  • 9李铁军,康楷,宋建宁,胡瓒斓,Tong-Chuan He,张秉强,张才全.RNA干扰抑制结肠癌细胞血管内皮生长因子表达[J].中国生物工程杂志,2007,27(8):14-18. 被引量:1
  • 10Holen T,Amarzguioui M, Babaie E, et al. Similar behav- iour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway[J]. Nucleic Adds Res, 2003,31 (9): 2401-2407.

二级参考文献11

  • 1Potgens A J, Westphal H R, Waal R M, et al. The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol Chem Hoppe Seyler, 1995,376:57 - 70
  • 2Kraizer Y, Mawasi N, Seagal J, et al. Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem Biophys Res Commun, 2001, 287:209 - 215
  • 3Lu P Y, Xie F Y, Woodle M C. Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med, 2005,11 (3) :1004 - 1013
  • 4Bernstein E, Candy A A, Hammond S M, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 2001, 409(6818): 363-366
  • 5Agami R. RNAi and related mechanisms and their potential use for therapy. Curr Opin Chem Biol, 2002, 6:829 -834
  • 6Mulkeen A L, Silva T, Yoo P S, et al. Short interfering RNA- mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg,2006,141 (4) :367 - 374
  • 7Warmenes F, Ciafre S A, Niola F, et al. Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther, 2005,12(12) :926 -934
  • 8Murata M, Takanami T, Shimizu S, et al. Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor ( VEGF ). Curt Eye Res,2006,31 (2) :171 - 180
  • 9Paul C P, Good P D, Winer I, et al. Effective expression of small interfering RNA in human cells. Nat Biotechnol, 2002, 20:505-508
  • 10Kerbel R, and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2:727 -739

同被引文献22

  • 1Chen CY, Lin YS, Chen CL, et al. Targeting annexin A2 reducestumorigenesis and therapeutic resistance of nasopharyngeal carcino-ma[ J]. Oncotarget,2015 , 6(29) :26946 - 26959.
  • 2Choi DS, Yang JS, Choi EJ, et al. The protein interaction net-work of extracellular vesicles derived from human colorectal cancer.
  • 3谢蕊,李燕京,隋红,等.ANXA2调节胃癌细胞的增殖、侵袭和转移[J].临床与病理杂志,2015,35(21):S78-S79.
  • 4Tristante E,Martinez CM,Jim6nez S,et al. Association of acharacteristic membrane pattern of annexin A2 with high invasive-ness and nodal status in colon adenocarcinoma [ J ]. Transl Res,2015,166(2):196-206.
  • 5Gurluier E, Guner OS, Tumay LV, et al. Serum annexin A2 lev-els in patients with colon cancer in comparison to healthy controlsand in relation to tumor pathology [ J ]. Med Sci Monit, 2014,3(20) :1801 -1807.
  • 6Tsukamoto H, Tanida S, Ozeki K, et al. Annexin A2 regulates adisintegrin and metalloproteinase 17-mediated ectodomain sheddingof pro-tumor necrosis factor-a in monocytes and colon epithelialcells [J]. Inflamm Bowel Dis, 2013,19(7) : 1365 ~ 1373.
  • 7Elena Tristantea, Carlos M. Martlnezb, Sofia Jim6nezc, et al. As-sociation of a characteristic membrane pattern of annexin A2 withhigh invasiveness and nodal status in colon adenocarcinoma[ J].Translational Research, 2015 , 166(2):196-206.
  • 8Qi Zhang, Zhongsheng Zhao, Yingyu Ma, et al. Combined ex-pression of S100A4 and Annexin A2 predicts disease progressionand overall survival in patients with urothelial carcinoma[ J]. Uro-logic Oncology, 2014,32(6) :798 -805.
  • 9秦呈林,查文章,姚登福,张海健.膜联蛋白A2异常表达与消化道肿瘤发生、发展的关系[J].中华临床医师杂志(电子版),2012,6(4):103-106. 被引量:4
  • 10陆少林,张海健,顾星,时运,钱琦,张洁,王司晔,姚登福.肝组织及血ANXA2表达异常对肝癌诊断与鉴别的价值[J].胃肠病学和肝病学杂志,2013,22(8):808-811. 被引量:2

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部